摘要
近年来银屑病免疫学发病机制的研究得到了令人瞩目的进展,为银屑病的治疗带来了崭新的前景,特别是针对重要的免疫发病环节已经研制出了多种靶向外用治疗药物,多项临床Ⅰ、Ⅱ期试验中的几类外用制剂主要瞄准JAK/STAT、PED4、IRS-1、VEGF受体和TrkA等细胞因子或选择性抑制信号通路的小分子抑制剂为靶点,为银屑病的外用药物治疗提供了更多新的选择。
In recent years,the research progresses in immunological mechanisms of psoriasis and genetic engineering have brought the prospect in treatment of psoriasis. Several newagents selectively targeting the small molecules of cytokines and signaling pathways are available. The phase I and II clinical trials on inhibitors of JAK/STAT,PED4,IRS-1,VEGF receptors and TrkA are underway,which would provide more choices for topical treatment of psoriasis in the future.
作者
黄韬
龚瑜
史玉玲
HUANG Tao;GONG Yu;SHI Yu-ling(Dept. of Dermatology, Tenth People＇s Hospital, Tongji University, Shanghai 200072, Chin)
出处
《同济大学学报（医学版）》
CAS
2018年第2期22-25,共4页
Journal of Tongji University(Medical Science)
基金
国家自然科学基金(81673050
81301356)
上海市自然科学基金(16ZR1426800)
关键词
银屑病
外用药
信号通路
小分子抑制剂
psoriasis
topical treatment
signaling pathways
small molecules inhibitor
